Recently diagnosed with HIV? Click here

HAART dramatically improves survival in relation to neurological AIDS diseases

Story • Serena Maluwisa • 1 December 2007

Survival after diagnosis with AIDS-related neurological illnesses has improved since the advent of HAARTHighly Active AntiRetroviral Therapy ??? aggressive treatment of HIV infection using several different drugs together., according to an abstract presented to the eleventh European AIDS Conference (EACS). Furthermore, patients on ARVA medication or other substance which is active against retroviruses such as HIV. regimens containing a higher number of drugs that crossed the ‘blood-brain barrier’ and got into the central nervous system (CNS) had better survival rates. However the study also found that survival from two conditions – cryptococcal meningitis and progressive multifocal leukoencephalopathy (PML) - has not improved since the early days of HAART, and in the case of PML has got slightly worse since 1998.

Amongst the most feared symptoms of AIDS are those that affect the brain. However an analysis of data from the French Hospital Database of HIV, a large cohortIn epidemiology, a group of individuals with some characteristics in common. A cohort study is a special kind of clinical trial which looks at a treatment or treatment strategy in a cohort of people. study of HIV patients conducted by he French INSERM research institute presented to the conference that survival rates from four of them – toxoplasmosis, dementia resulting from HIV encephalopathy, PML and cryptococcal meningitis – had improved dramatically since the advent of HAART.

In the pre-HAART era, less than half of patients diagnosed with any of these conditions were expected to be alive a year later, and in the case of AIDS dementia and PML that fell to one in five. Survival rates immediately improved when HAART came along. One year survival rates for the four conditions were 73 percent, 55 percent, 56 percent and 76 percent between 1996 and 1998. Since then survival from toxoplasmosis and HIV dementia have continued to improve and one-year survival now stood at 80 percent and 70 percent respectively for the two conditions.

Survival with AIDS-related meningitis had improved non-significantly and was now at 86 percent. But survival with PML had actually got marginally worse and now stood at 49 percent.

Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Story was first published on 1 December 2007 — more than four years ago.

While the content of this story was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.